Composition, form of production and packaging
Capsules hard gelatinous, size No. 0, white, cylindrical with hemispherical ends; the contents of the capsules are white or almost white powder.
1 caps.
piracetam 400 mg
cinnarizine 25 mg
Excipients: magnesium carbonate basic, calcium stearate.
Composition of the shell: gelatin, glycerol, nipagin, nipazole, sodium lauryl sulfate, purified water, titanium dioxide.
10 pieces. - packings cellular planimetric (6) - packs cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the print edition of 2007.
PHARMACHOLOGIC EFFECT
Combined drug with pronounced antihypoxic, nootropic and vasodilating action.
Piracetam activates metabolic processes in the brain by enhancing energy and protein metabolism, accelerating the utilization of glucose by cells and increasing their resistance to hypoxia. Improves interneuronal transmission in the central nervous system and regional blood flow in the ischemic zone.
Cinnarizin - a blocker of calcium channels, inhibits the entry of calcium ions into cells and reduces their content in the depot of the plasmolemma, reduces the tone of the smooth muscles of arterioles, reduces their reaction to biogenic vasoconstrictors (epinephrine, norepinephrine, dopamine, angiotensin, vasopressin). It has a vasodilating effect (especially with respect to cerebral vessels, enhancing the antihypoxic effect of piracetam), without having a significant effect on blood pressure. It shows moderate antihistamine activity, reduces the excitability of the vestibular apparatus, increases the tone of the sympathetic nervous system. Increases the elasticity of erythrocyte membranes, their ability to deform, reduces the viscosity of the blood.
PHARMACOKINETICS
Data on the pharmacokinetics of the drug Piracazine are not available.
INDICATIONS
- disorders of cerebral circulation (ischemic stroke, recovery period after hemorrhagic stroke);
- encephalopathy of different genesis;
- intoxication;
- Brain trauma;
- CNS diseases, accompanied by a decrease in intellectual-mnestic functions;
- psychoorganic syndrome with symptoms of asthenia and adynamia predominating;
- asthenic syndrome;
- labyrinthopathy;
- Meniere's syndrome;
- prevention of kinetosis;
- lagging behind the intellectual development of children;
prevention of migraine.
DOSING MODE
Adults prescribe 1-2 capsules. 3 times / day for 1-3 months depending on the severity of the disease. The course of treatment - 2-3 times a year.
Children over 5 years of age are prescribed 1-2 caps. 1-2 times / day.
SIDE EFFECT
Possible: irritability, sleep disturbances, nausea, dyspepsia.
CONTRAINDICATIONS
- liver failure;
- kidney failure;
- Pregnancy;
- lactation (breastfeeding);
- Children's age till 5 years;
- Hypersensitivity to the components of the drug.
PREGNANCY AND LACTATION
Piracyzin is contraindicated in pregnancy and lactation (breastfeeding).
APPLICATION FOR FUNCTIONS OF THE LIVER
The drug is contraindicated in renal failure.
APPLICATION FOR VIOLATIONS OF THE FUNCTION OF KIDNEYS
The drug is contraindicated in case of liver failure.
APPLICATION FOR CHILDREN
The drug is contraindicated for children under 5 years.
Children over 5 years of age are prescribed 1-2 caps. 1-2 times / day.
OVERDOSE
To date, no cases of an overdose of the drug Pyracezin have been reported.
DRUG INTERACTION
With simultaneous application with Piratsinom it is possible to enhance the effects of nootropic, adaptogenic, hypotensive drugs, as well as drugs depressing the activity of the central nervous system (including ethanol).
Piracyzin improves the tolerability of antipsychotic drugs and tricyclic antidepressants.
When combined, Piratsin reduces the effect of hypertensive drugs.
TERMS OF RELEASE FROM PHARMACY
The drug is released by prescription.
TERMS AND CONDITIONS OF STORAGE
List B. The drug should be stored in a dry, protected from light and out of reach of children at a temperature of 15 В° to 25 В° C. Shelf life - 2 years.
